Novo Nordisk expects 5-9 percent sales growth in 2021

Pharmaceutical company Novo Nordisk exceeds Q4 revenue guidance and aims for a 5-9 percent increase in local currency in 2021. This would be the same level as the sales for all of 2020.

Photo: Stine Tidsvilde

At the end of 2021 Novo Nordisk hopes to have scraped together a 5-9 percent revenue growth with a 4-8 percent higher operational result, both measured in local currency.

In DKK terms, however, Novo expects the growth will be around 4 percentage points lower as regards the top line and operating profit, according to the pharmaceutical giant's annual financial report published Wednesday morning.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs